Compare Li Auto Inc (LI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Li Auto Inc trades at $11.3 (market cap $11.27B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Li Auto Inc is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 102 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LI | SYRE | |
|---|---|---|
Market Cap | $11.27B | $7.52B |
Volume | 3,921,121 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.72 | $108.92 |
52-Week Low | $10.69 | $22.18 |
Typical Hold Time | 102 Days | 0 Days |
Enterprise Value | $673.48M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.75, up 3.07% today but near 52-week lows amid declining delivery volumes and negative earnings surprises. The stock shows bearish technical signals with mixed analyst sentiment (43.75% buy, 50% hold). Recent Q2 2026 results missed expectations with a net loss, though vehicle margins improved to 9.4%. New model launches (Li i9, MEGA) and global expansion plans contrast with cash burn concerns, with operating cash flow negative $8.6B in 2025.
Outlook remains challenged by intense EV competition and China's auto market slowdown, but the company's strong balance sheet ($112.8B cash) provides cushion. Analyst consensus target of $15.18 suggests 29% upside if execution improves, though near-term risks from volume pressure and margin compression persist. The stock offers value at 0.78 P/S but requires monitoring of delivery trends and cost controls.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
